Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesCIViC databaseBeyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Practical management of myelofibrosis with ruxolitinib.Safety considerations when treating myelofibrosis.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?The evolution and clinical relevance of prognostic classification systems in myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.Prognosis of Primary Myelofibrosis in the Genomic EraMyelofibrosis: an update on drug therapy in 2016.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceTargeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.Primary myelofibrosis: current therapeutic options.Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.Developmental Therapeutics in Myeloproliferative Neoplasms.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhiSOHO State-of-the-Art Update and Next Questions: MPN.Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
P2860
Q26738514-5B4B78AB-FE34-4726-A00B-C3835574B131Q26752940-6ACC1999-4108-4CDA-A574-3E4B1D352107Q27612411-63A9A0DE-8549-4D4C-BEEE-494CBFD72EA9Q30399669-A48425AD-0956-4571-B7D6-2096FC26CE52Q33428259-7AC2EE85-FA9E-4DBD-B9B8-95E9A98649EEQ33432285-1CC9BAF5-0606-40EA-A325-8C935621A610Q33443246-83F1CF07-19FC-4CC6-9C5E-88C6893A5E3FQ34550417-55BF173E-3BAE-4F7C-AEFD-F0D388FE1918Q37046564-1884E7C6-927E-48FE-9C15-C2BFAE6E17D5Q37397491-611B4AA1-832E-441F-BD60-3202AD15615BQ38597994-2B38A328-55CA-4261-BA77-338D6A7EB6EBQ38667263-6E7979FF-B3D6-410B-88B3-2A45CD7B6E54Q38683077-1DEA4412-AAFA-48F4-B587-93CE2FB734EBQ38684435-5C479C49-ECA2-4E27-88F0-E4CB7662C6FCQ38691019-F6DC39BA-9366-4C90-966A-053A81D32D5EQ38695362-2430D668-8859-4EFF-891D-062677047F9DQ38786380-777F9E19-1ACF-47D6-B7B4-992AF1AF933AQ38926804-8A5C934B-3B40-469B-8F76-7A8876C9BFD1Q38989215-F81FAF4D-2BEE-46B8-91F2-E8EF17E60543Q39554738-00C19C1E-1695-4739-9CEF-44929584607DQ39770083-1930373E-4278-4523-A104-230929D4754DQ40197045-0A83D181-C326-4499-95C4-BF1CE02E31E5Q40854467-871EEC29-F6FA-4896-8FD5-6CE0198BD409Q40858775-54FFC416-9AE0-453C-8EAA-64F52CC24392Q41186952-2C3C7C17-2535-495D-922E-5304AA78CCB5Q41225286-948F291B-8000-4DA5-AA4F-894C65452E96Q41573002-4AC171F6-87D7-4236-BFE5-EA8BD140B997Q47815810-905E1E12-3869-417A-A6C9-6B6D317D8031Q48008083-B71B9D97-E1AB-4803-A216-29EB1D5715A6Q48309941-AFFFF0DB-2B5D-413A-99F8-0F2247609558Q48330476-1682F6BC-C78B-41AE-9CA2-2EA277DC1109Q49332507-6BA7E744-1E2E-4C42-8F7A-A245096947DDQ49580473-F4C63021-91B0-476B-BE25-DDF604A172D0Q51737052-6FADE14B-1D86-40E7-ACD3-72FD058E4D73
P2860
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Correlation of mutation profil ...... osis treated with ruxolitinib.
@ast
Correlation of mutation profil ...... osis treated with ruxolitinib.
@en
Correlation of mutation profil ...... osis treated with ruxolitinib.
@nl
type
label
Correlation of mutation profil ...... osis treated with ruxolitinib.
@ast
Correlation of mutation profil ...... osis treated with ruxolitinib.
@en
Correlation of mutation profil ...... osis treated with ruxolitinib.
@nl
altLabel
Correlation of mutation profil ...... rosis treated with ruxolitinib
@en
prefLabel
Correlation of mutation profil ...... osis treated with ruxolitinib.
@ast
Correlation of mutation profil ...... osis treated with ruxolitinib.
@en
Correlation of mutation profil ...... osis treated with ruxolitinib.
@nl
P2093
P2860
P50
P3181
P1433
P1476
Correlation of mutation profil ...... osis treated with ruxolitinib.
@en
P2093
Fabio P Santos
Kate J Newberry
Keyur P Patel
Madan Luthra
Mark J Routbort
Meenakshi Mehrotra
Rajesh Singh
Rajyalakshmi Luthra
Taghi Manshouri
P2860
P3181
P356
10.1182/BLOOD-2015-03-633404
P407
P577
2015-08-06T00:00:00Z